Instil Bio Announces Key Data on '2510 for Lung Cancer
In a significant presentation, Instil Bio, Inc. (NASDAQ: TIL) shared promising results regarding its innovative treatment, ‘2510. This groundbreaking monotherapy has shown potential effectiveness for patients suffering from previously treated squamous non-small cell lung cancer (sq-NSCLC). The presentation took place during a prominent conference dedicated to lung cancer research.
Highlights of the Presentation
During this engagement, Instil Bio was excited to reveal preliminary data highlighting an overall response rate (ORR) of 35.3% among 23 patients treated with ‘2510. These patients had previously experienced failures with the PD-(L)1 inhibitors and platinum-doublet chemotherapy. Impressively, the responses were particularly noted in those with lower PD-L1 tumor proportion score (TPS) values, showcasing ‘2510's potential for broader applicability.
Details on the Clinical Study
This Phase 1 study aimed to evaluate the safety and efficacy of ‘2510 among individuals with sq-NSCLC who had undergone prior treatments. The dosage regimen varied, with patients administered different levels of the drug, predominantly at a higher dose of 20 mg/kg Q2W. The presented data reflects 17 efficacy evaluable individuals, indicating a noteworthy response that gives hope for patients with limited options.
Safety and Tolerability Observations
Throughout the Phase 1 trial, ‘2510 was reported as safe and well-tolerated. Most patients experienced manageable low-grade infusion reactions during their first treatment cycles. However, there were some cases involving Grade 3 VEGF-related adverse effects, which included incidents of proteinuria and bleeding. With ongoing enrollment at the 20 mg/kg Q2W dose level, the study continues to explore the optimal application of this therapy.
Insights from Instil Bio's CMO
Jamie Freedman, M.D., Ph.D., Chief Medical Officer at Instil Bio, expressed optimism about the preliminary outcomes, stating, “'2510 was designed for potential best-in-class activity with a VEGF trap to neutralize VEGF ligands effectively while enhancing ADCC for direct tumor killing.” These insights indicate the potentially pioneering role of ‘2510 within the arena of treatments aimed at improving patient outcomes.
About Instil Bio
Instil Bio is dedicated to advancing novel therapies through innovation and commitment to research. Its flagship asset, AXN-2510, is making strides in the challenging landscape of cancer treatment, specifically targeting the nuances of multiple solid tumors. Further information on Instil Bio’s initiatives can be found on their official website.
Frequently Asked Questions
What is ‘2510 and what does it target?
'2510 is a bispecific antibody that targets PD-L1 and VEGF, designed to enhance anti-tumor activity in certain cancer types.
How effective is ‘2510 based on the recent study?
The recent study indicated an ORR of 35.3% in sq-NSCLC patients previously treated with standard therapies.
What safety concerns were observed during the trial?
Most side effects were manageable, with some patients experiencing low-grade infusion reactions and a couple of Grade 3 adverse events.
Who presented the data about ‘2510?
ImmuneOnco Biopharmaceuticals presented the data during the World Conference on Lung Cancer.
Where can I find more information about Instil Bio?
More details are available on Instil Bio’s official website, where you can explore their research and innovations in therapy.
